Citius Pharmaceuticals, Inc.
CTXR Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$0.40
KIRA · Stoqly’s AI analyst, in plain words
- Citius Pharmaceuticals, Inc. lost $39.7M in fiscal 2025.
- Citius Pharmaceuticals, Inc. owes $296M more than it holds in cash.
Market cap
$10.6M
P/E
—
Revenue
—
Net income
−$39.7M
Free cash flow
—
Operating margin
—
Citius Pharmaceuticals, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$39.7M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Citius Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- September 30, 2025
- Latest annual report
- 10-K · Dec 23, 2025
- Legal name
- Citius Pharmaceuticals, Inc.
- CIK
- 0001506251
Citius Pharmaceuticals, Inc. · CTXR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.1M | $0.1M | — | — | — |
| Revenue growth | 0.0% | 0.0% | — | — | — |
| Operating margin | −26,146.6% | −37,017.8% | — | — | — |
| Net income | −$23.1M | −$33.6M | −$32.5M | −$39.4M | −$39.7M |
| Net margin | −25,616.0% | −37,378.4% | — | — | — |
| Diluted EPS | −$0.23 | −$0.23 | −$5.57 | −$5.97 | −$3.38 |
| Cash | |||||
| Cash from operations | −$24.3M | −$28.4M | −$29.1M | −$28.2M | −$26.6M |
| Capital expenditure | $0.0M | — | — | — | — |
| Free cash flow | −$24.3M | — | — | — | — |
| FCF margin | −26,952.6% | — | — | — | — |
| Share count change | 177.3% | 34.5% | −95.9% | 11.2% | 64.5% |
| Debt and strength | |||||
| Cash and short-term investments | $70.1M | $41.7M | $26.5M | $3.3M | $4.3M |
| Debt incl. finance leases | — | — | — | — | $300M |
| Shareholders' equity | $132M | $103M | $90.8M | $70.1M | $67.6M |
| Current ratio | 18.3x | 9.8x | 5.9x | 0.4x | 0.6x |
| Interest coverage | −2,178.9x | — | — | — | −143.9x |
| Returns and quality | |||||
| Return on capital | — | — | — | — | −8.4% |
| Return on equity | −27.8% | −28.6% | −33.6% | −49.0% | −57.8% |
| Return on tangible equity | −19.9% | −36.0% | −41.4% | −66.2% | −64.3% |
| Piotroski F-score | 2 | 2 | — | — | — |
| Altman Z'' | 14.2 | 6.8 | 2.2 | −7.5 | −7.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Citius Pharmaceuticals, Inc. · CTXR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.40 a share, the company is worth $10.6M.
Source: SEC EDGAR XBRL filings (CIK 0001506251). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.